




**UNIVERSITI PUTRA MALAYSIA**

**PREPARATION, CHARACTERIZATION, AND PRELIMINARY  
PHARMACOKINETIC STUDIES ON COMPLEX OF ZERUMBONE  
WITH HYDROXYPROPYL- $\beta$ -CYCLODEXTRIN**

**ELTAYEB ELAMIN MOHAMMED EID**

**IB 2012 3**

**PREPARATION, CHARACTERIZATION, AND PRELIMINARY  
PHARMACOKINETIC STUDIES ON COMPLEX OF ZERUMBONE WITH  
HYDROXYPROPYL- $\beta$ -CYCLODEXTRIN**



**By**

**ELTAYEB ELAMIN MOHAMMED EID**

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,  
in Fulfilment of the Requirements for the Degree of Doctor of Philosophy**

**March 2012**

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Doctor of Philosophy

**PREPARATION, CHARACTERIZATION, AND PRELIMINARY  
PHARMACOKINETIC STUDIES ON COMPLEX OF ZERUMBONE WITH  
HYDROXYPROPYL- $\beta$ -CYCLODEXTRIN**

**By**

**ELTAYEB ELAMIN MOHAMMED EID**

**March 2012**

**Chairman: Ahmad Bustamam Abdul, PhD**

**Faculty: Institute of Bioscience**

Zerumbone (ZER) is a mono-sesquiterpene compound derived from ginger zerumbet smith. It has been reported that, ZER showed a significant activity in both *in vivo/in vitro* studies for different types of cancers such as cervical, colon, liver and breast cancer.

To facilitate the *in vivo* characterization of ZER, a reversed-phase HPLC and UPLC-MS/MS methods were developed and validated according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and Food and Drug Administration (FDA) guidelines.

Due to the high lipophilicity ( $\log P > 5$ ) and very limited water solubility of ZER, the bioavailability needs to be increased so that high blood levels can be obtained for moderate doses. In addition low water solubility contribute to its high protein binding that will leads to low therapeutic free ZER concentration and further successive doses will be imposed for the cancer therapy that will not preferable in clinical

environment, and preclude intravenous (i.v.) loading as well. Therefore, solubility and stability of ZER are essential physico-chemical properties that must be proved in early stages of drug development process.

Hydroxypropyl- $\beta$ -cyclodextrin (HP $\beta$ CD) was used in this study to increase the water solubility of ZER as well as its stability. The solubility of ZER was increased > 100 folds by 0.05M HP $\beta$ CD in water. The ZER/ HP $\beta$ CD complexes were characterized by phase solubility diagram, in which an A<sub>L</sub> –isotherm type was investigated. The thermodynamic parameters: enthalpy change ( $\Delta H^\circ$ ), entropy change ( $\Delta S^\circ$ ) and Gibbs free energy ( $\Delta G^\circ$ ) of the complexes were determined in the temperatures range (293-298 °K) using Van't Hoff equation. Differential scanning calorimetry (DSC) was used to confirm the formation of the inclusion complexes. Fourier Transform infra-red spectroscopy (FT-IR), X-ray diffraction (XRD) and <sup>1</sup>H, <sup>13</sup>C nuclear magnetic resonance (NMR) were also used to estimate the stoichiometry of the complexes. Molecular mechanics (MM) was used to further scrutinize the mechanism of complexation between ZER and HP $\beta$ CD, using theoretical semi-empirical calculation PM6.

Pure ZER and ZER/ HP $\beta$ CD complex were found to decompose with acid, base, oxidation and reduction; however, ZER/ HP $\beta$ CD complex was stable in dry heat compare with pure ZER that decomposed completely. The *in vitro* dissolution study of ZER from the complex was follow first order kinetics that is independent of concentration, as well as Hugchi model kinetics.

The second objective of the study was to determine the parenteral dosage form of ZER through *in vivo* studies. ZER suspended in carboxymethyl cellulose sodium salt (CMC) was for intraperitoneal while ZER/HP $\beta$ CD inclusion complex for intravenous application. New Zealand white rabbits, Sprague-Dawley rats and BALB/c mice were dosed with ZER or ZER/ HP $\beta$ CD complex at equivalent doses of 10, 20 and 40 mg ZER/kg body weight respectively. The study showed that ZER/HP $\beta$ CD complex has improved the pharmacokinetic parameters over pure ZER. Thus the aqueous parenteral dosages of ZER are best achieved through the use of HP $\beta$ CD in a complex form.

The allometric scaling approach is analyzed and the predictive performance for this scaling method in estimating human systemic clearance, volume of distribution, area under the curve and plasma half-life is evaluated. The results show that the formulation of zerumbone in hydroxypropyl- $\beta$ -cyclodextrin as an intravenous preparation has a good correlation between the animal species and human pharmacokinetics based on the species body weight.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**PERSEDIAAN, PENCIRIAN, DAN KAJIAN FARMAKOKINETIK AWAL  
KOMPLEKS ZERUMBON DENGAN HIDROKSIPROPIL- $\beta$ -  
SIKLODEKSTRIN**

Oleh

**ELTAYEB ELAMIN MOHAMMED EID**

Mac 2012

**Pengerusi: Ahmad Bustamam Abdul, PhD**

**Fakulti: Institut Biosains**

Zerumbon (ZER) merupakan sebatian mono-seskuiterpena daripada halia zerumbet smith. Mengikut laporan, ZER menunjukkan kegiatan *in vivo* dan *in vitro* tererti terhadap pelbagai jenis kanser seperti kanser serviks, kolon, hati dan payudara. Untuk membantu dalam pencirian ZER, kaedah HPLC dan UPLC-MS/MS telah dikembangkan dan disahkan mengikut garis panduan International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) dan Food and Drug Administration (FDA).

Oleh sebab lipofisiti tinggi ( $\log P > 5$ ) dan kelarutan air ZER rendah, maka bioperolehan perlu ditingkat untuk memastikan kepekatan darah tinggi sekalipun dos sederhana digunakan. Kelarutan air yang rendah menyumbang kepada pengikatan protein tinggi dan menghasilkan kepekatan ZER terapeutik rendah. Maka, dalam terapi kanser, dos tambahan diperlukan untuk memastikan kepekatan darah terapeutik tercapai. Dalam keadaan klinikal, pemuatan berlebihan sebatian ini mungkin tidak diingini. Dengan demikian, objektif pertama kajian ini ialah untuk

menentukan kelarutan dan kestabilan ZER, kerana ciri fizikokimia perlu ditentukan terlebih dahulu sebelum ianya boleh dikembangkan kepada drug berpotensi.

Hidroksipropil- $\beta$ -siklodekstrin (HP $\beta$ CD) telah digunakan dalam kajian ini untuk meningkatkan kelarutan dan kestabilan ZER. Kelarutan ZER telah meningkat > 100 kali ganda apabila 0.05 M HP $\beta$ CD dalam air telah diguna sebagai pelarut. Kompleks ZER/HP $\beta$ CD yang terbentuk dalam larutan dicirikan mengguna gambar rajah kelarutan fasa dan jenis A<sub>T</sub>-isoterm diselidik. Parameter termodinamik: perubahan entalpi ( $\Delta H^\circ$ ), perubahan entropi ( $\Delta S^\circ$ ) dan tenaga bebas Gibbs ( $\Delta G^\circ$ ) ditentukan pada 293-298 °K mengguna persamaan Van't Hoff. Kalorimetri imbasan pembeza (DSC) kemudian diguna untuk memastikan kompleks rangkuman telah terbentuk. Penganggarkan stiokiometri kompleks tersebut dilakukan melalui spektroskopi infra-merah transformasian Fourier (FT-IR), belauan sinar-X (XRD) dan resonans magnet nucleus <sup>1</sup>H, <sup>13</sup>C. Mekanik molecule (MM) diguna seterusnya untuk menentukan mekanisme pembentuk kompleks antara ZER dan HP $\beta$ CD, dengan mengguna pengiraan separa empiric PM6.

ZER tulen dan kompleks ZER/HP $\beta$ CD didapati tercerai selepas diperlakukan asid, bes, pengoksidaan dan penurunan. Bagaimanapun, kompleks ZER/HP $\beta$ CD masih stabil dalam haba kering, sambil ZER tercerai sepenuhnya. Kajian penceraian *in vitro* terhadap kompleks ZER/HP $\beta$ CD didapati menepati kinetik terbit pertama yang bersandar kepekatan dan kinetic model Hugchi.

Objektif kedua kajian ini ialah menentukan bentuk dos parenteral untuk ZER dan ini dilakukan melalui kajian *in vitro*. ZER diampaiakan dalam garam natrium selulosa karboksimetil (CMC) untuk aplikasi intraperitoneum sambil kompleks rangkuman

ZER/HP $\beta$ CD pula untuk intravena. Arnab New Zealand putih, tikus Sprague-Dawley dan mencit BALB/c disuntik dengan ZER atau kompleks ZER/HP $\beta$ CD dengan dos setara ZER pada kadar 10, 20 dan 40 ZER/kg berat badan. Kajian ini telah menunjukkan yang parameter farmakokinetik kompleks ZER/HP $\beta$ CD lebih baik daripada ZER tulen. Kesimpulannya, dos parenteral akueous ZER lebih mudah dicapai dengan menguna HP $\beta$ CD dalam bentuk kompleks.

Prestasi ramalan ZER ditentukan melalui penskalaan alometri untuk menganggarkan pembersihan sistemik manusia, isipadu pengedaran dan separuh hayat plasma. Hasil kajian menunjukkan yang farmakokinetik ZER dalam rumusan HP $\beta$ CD sebagai persediaan intravena yang dilakukan dalam kajian haiwan, menyarankan ada perkaitan baik dengan farmakokinetik manusia berasas berat badan.



## ACKNOWLEDGEMENTS

Having reached the end of a long road that has been challenging both mentally and emotionally, I can now reflect on the factors that have truly influenced my journey.

Thanks a lot for ALLAH SWT for let me to reach this stage.

I have been blessed to be surrounded by wonderful people. First I would like to thank my research advisor, Dr Ahmad Bustamam Abdul for believing in me, presenting me with the challenge, and allowing me to meet that challenge. Thank you for your support and guidance as advisor. Thanks also to remaining members of my Ph.D. committee, Prof.Dr. Rasedee Abdulla who is gives me a lot from his own time and efforts. Also many thanks to Prof. Dr. Mohammed Aspollah Sukari for his guidance and support.

I would like also to take this opportunity to thanks Prof. FakhrEldin O. Suliman for his extensive support during my studies.

I would like to thank all of the people who have had an influence on the progress of this project. First and foremost, thanks to Eng. Mohammed Mustafa Alhabshi for his technical support and help, Dr. Mohammed Mustafa Mohammed Ibrahim for his deep and valuable guidance. The thanks also extended to my friends in LIVES who they help a lot and many thanks for them.

My great thanks to my wife Dr. Nahed M. Hassona who was give me her expensive assets up to the emotional support from the starting till to the end of this project. So, I never ever forget her efforts towards my success in this project, thanks for her a lot. I

hope from ALLAH to help me to let her in a great feeling that we are in the same body.

Finally, I wish to express my deepest appreciation to my father who was giving me a great emotional support during my study period for the doctoral program.

Also, I would like to thanks my brother Dr.Muatasim E.M.Eid, for his respective concern and efforts during my doctoral program.

My greatest attitude to my all family members: Mohammed E.M.Eid, Mohammed Mustafa Gadal, Teacher Souad, Niamat, Basamat, Ehsan, Amna, Fatima ,Seham , Hafsa and Gewaria, for their support and advices.

I certify that a thesis Examination committee has met on 21. March.2012 to conduct the final examination of : **ELTAYEB ELAMIN MOHAMMED EID** on his Doctor of Philosophy thesis entitled “preparation, characterization and preliminary pharmacokinetic studies on complex of zerumbone with hydroxypropyl- $\beta$ -cyclodextrin” in accordance with the Universities and University college act 1971 and the constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination committee were as follows:

**Y.H. Taufiq Yap, Ph.D.**

Professor,  
Faculty of Science  
Universiti Putra Malaysia  
(Chairman)

**Di Sidik Silong, Ph.D.**

Associate Professor,  
Faculty of Science  
Universiti Putra Malaysia  
(Internal Examiner)

**Mohammed Ibrahim bin Noordin, Ph.D.**

Associate Professor,  
Department of Pharmacy  
Faculty of Medicine  
University of Malaya  
(External Examiner)

**Steven H. Neau, Ph.D.**

Professor,  
Philadelphia College of Pharmacy  
University of the Sciences  
Philadelphia, PA, USA  
(External Examiner)

---

**SEOW HENG FONG, Ph.D.**

Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of **Doctor of Philosophy**.

The members of the Supervisory Committee were as follows:

**Ahmad Bustamam Abdul, PhD**

Associate Professor  
Faculty of Medicine and Health Sciences and,  
University Putra Malaysia  
(Chairman)

**Rasedee Abdullah, PhD**

Professor  
Faculty of Veterinary Medicine  
Universiti Putra Malaysia  
(Member)

**Mohd Aspollah Sukari, PhD**

Professor  
Faculty of Science  
Universiti Putra Malaysia  
(Member)

---

**BUJANG BIN KIM HUAT, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

## DECLARATION

I declare that the thesis is my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.



---

**ELTAYEB ELAMIN MOHAMMED EID**

Date: 21 March 2012

## TABLE OF CONTENTS

	Page
<b>ABSTRACT</b>	<b>i</b>
<b>ABSTRAK</b>	<b>iv</b>
<b>ACKNOWLEDGEMENTS</b>	<b>vii</b>
<b>APROVAL</b>	<b>ix</b>
<b>DECLARATION</b>	<b>xi</b>
<b>LIST OF TABLES</b>	<b>xiv</b>
<b>LIST OF FIGURES</b>	<b>xvi</b>
<b>LIST OF APPENDICES</b>	<b>xx</b>
<b>LIST OF ABBREVIATIONS</b>	<b>xxi</b>
<b>CHAPTER</b>	
<b>1 INTRODUCTION</b>	<b>1</b>
Objectives of the study	9
<b>2 LITERATURE REVIEW</b>	<b>10</b>
Natural Products	10
Ginger	11
Zingiber zerumbet	12
Zerumbone (ZER)	13
Drug Development Process	19
Analytical development method and Validation	25
Complexation Approaches	31
Cyclodextrins	35
Mechanism and Driving force s of Complexation in Solution	43
Characterization of cyclodextrin inclusion complex in solution state	45
Pharmacokinetic	47
<b>3 HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC (HPLC) METHOD FOR DETERMINATION OF ZERUMBONE (ZER) IN HUMAN PLASMA</b>	<b>52</b>
Introduction	52
Materials and Methods	53
Results and Discussion	57
Conclusion	63
<b>4 LIQUID CHROMATOGRAPHY –TANDEM MASS SPECTROSCOPIC METHOD FOR DETERMINATION OF ZERUMBONE IN HUMAN PLASMA</b>	<b>64</b>
Introduction	64
Materials and Methods	65
Results and Discussion	70
Conclusion	83

<b>5</b>	<b>INCLUSION COMPLEXES OF ZERUMBONE WITH HYDROXYPROPYL-B-CYCLODEXTRIN (HPBCD) IN AQUEOUS SOLUTION</b>	<b>85</b>
	Introduction	85
	Materials and Methods	87
	Results and discussion	93
	Conclusion	111
<b>6</b>	<b>IN VITRO DISSOLUTION RATE AND FORCED DEGRADATION STUDIES OF ZERUMBONE- HYDROXYPROPYL-B-CYCLODEXTRIN (HPBCD) INCLUSION COMPLEX</b>	<b>112</b>
	Introduction	112
	Material and Methods	114
	Results and discussion	120
	Conclusion	142
<b>7</b>	<b>PHARMACOKINETICS OF ZERUMBONE- HYDROXYPROPYL-B-CYCLODEXTRIN (HPBCD) INCLUSION COMPLEX IN THREE ANIMAL SPECIES MICE, RATS AND RABBITS AND INTERSPECIES SCALING OF ITS PHARMACOKINETIC PARAMETERS</b>	<b>143</b>
	Introduction	143
	Materials and Methods	145
	Results and discussion	149
	Conclusion	159
<b>8</b>	<b>GENERAL CONCLUSION</b>	<b>160</b>
	<b>BIBLIOGRAPHY</b>	<b>162</b>
	<b>APPENDIXES</b>	<b>178</b>
	<b>STUDENT BIODATA</b>	<b>203</b>
	<b>LIST OF PUBLICATION</b>	<b>204</b>